Hundreds of thousands of doses a new Ebola vaccine could be ready to send to West Africa within the next three months, NewLink Genetics CEO Charles Link said Tuesday.
"We think by the end of the year we could have hundreds of thousands of doses, if the dose that's chosen is a moderate-size dose," he said. "It could be hundreds of thousands of doses, maybe more."
On CNBC's "Fast Money," Link said that Phase 1 data of NewLink's vaccine is expected in December 2014.
The drug is currently being tested on 500 human volunteers in the United States, Britain, Germany, Switzerland, Mali, Gabon and Kenya. That Phase 1 data will determine the efficacy of the drug based on the human's antibody response to the vaccine.
Read More Ebola: A closer look at this 'frightening disease'
"That data will be used to make a choice to then launch the larger scale trial (in West Africa) in a phased version in January of next year but it's a little hard to nail that date down today," said Link.
GlaxoSmithKline, Johnson & Johnson, Inovio Pharmaceuticals and Sarepta Therapeutics are also among the companies developing Ebola vaccines.